Levocarnitine Decreases Intradialytic Hypotension Episodes: A Randomized Controlled Trial
| Autor: | Daniel Alberto Gallegos-Arguijo, Juan Francisco Ortiz-Treviño, Héctor Raúl Ibarra-Sifuentes, Concepción Sánchez-Martínez, César Pezina-Cantú, Rolando Jacob Martínez-Granados, Sergio A. Castillo-Torres, Jesus E. Cuellar-Monterrubio, Alexandro Atilano-Díaz, Edgar de Jesús Martínez-Guevara, Guillermo Delgado-García, Angel N. Del Cueto-Aguilera, José Guadalupe Martínez-Jiménez, Jesús Cruz-Valdez, Raymundo Vera-Pineda |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
business.industry
medicine.medical_treatment Incidence (epidemiology) 030232 urology & nephrology Hematology 030204 cardiovascular system & hematology Placebo Levocarnitine law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Nephrology law Anesthesia medicine Hemodialysis Intradialytic hypotension Complication business Application methods |
| Zdroj: | Therapeutic Apheresis and Dialysis. 21:459-464 |
| ISSN: | 1744-9979 |
| DOI: | 10.1111/1744-9987.12553 |
| Popis: | Intradialytic hypotension is common complication in stage 5 chronic kidney disease patients on hemodialysis. Incidence ranges from 15 to 30%. These patients have levocarnitine deficiency. A randomized, placebo-controlled quadruple-blinded trial was designed to demonstrate the levocarnitine efficiency on intradialytic hypotension prevention. Patients were randomized into four groups, to receive levocarnitine or placebo. During the intervention period, levocarnitine and placebo was administered 0 and 30 min before each hemodialysis session, respectively. During the trial, 33 patients received 1188 hemodialysis sessions. We identified 239 (21.3%) intradialytic hypotension episodes. The intradialytic hypotension episodes were less frequent in the levocarnitine group (9.3%, 60 IH events) (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text